title: A case report of paclitaxel administered to a patient with platinum-refractory ovarian cancer on long-term hemodialysis.
abstract: We present the second case of a patient with platinum-refractory ovarian cancer who was treated safely with paclitaxel while on hemodialysis. Paclitaxel was administered at 175 mg/m2 as a 24-hour intravenous infusion on a nondialysis day. The patient tolerated this therapy well with minimal toxic reactions except for total alopecia and myelosuppression, which was unremarkable. Paclitaxel may be used in patients receiving long-term hemodialysis in the same dose schedule as in patients with normal renal function.
authors.affiliation: University of Texas, M.D. Anderson Cancer Center, Houston, USA.
authors.forename: O
authors.initials: O
authors.lastname: Balat
authors.forename: A P
authors.initials: AP
authors.lastname: Kudelka
authors.forename: C L
authors.initials: CL
authors.lastname: Edwards
authors.forename: C
authors.initials: C
authors.lastname: Verschraegen
authors.forename: R
authors.initials: R
authors.lastname: Mante
authors.forename: J J
authors.initials: JJ
authors.lastname: Kavanagh
mesh_terms: D000328:Adult; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000627:therapeutic use*; D006435:Renal Dialysis
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel